- Annual Meeting
- Practice Resources
- Study Groups
- ISOO – Oral Oncology
MASCC Mucositis Study Group
Chair: Sharon Elad, DMD MSc (Selad@urmc.rochester.edu) - USA
Study Group Minutes
Mission and Goals
The Mucositis Study Group's major goal is to improve outcomes of patients experiencing oral and gastrointestinal mucositis associated with anticancer therapies. This study group is a combined effort of MASCC and ISOO. Our objectives are to improve the design and conduct of clinical investigations, disseminate up-to-date educational information regarding mucositis, and serve as a resource for investigators in basic science, clinical, and health services research, as well as for industrial collaborators, clinicians, and patients.
Mucositis Main Guidelines Publication
Mucositis Guidelines Summary
Guideline Publications - View All Publications related to current and previous versions of the Guidelines
The MSG has created a patient-friendly version of the Clinical Practice Guidelines for the Management of Oral Mucositis. We hope it will be helpful for patients and for healthcare providers looking for resources for their patients.
Study Group News
MASCC/ISOO Clinical Practice Guidelines for Management of Mucositis Included in the National Guideline Clearinghouse
These Guidelines represent a major accomplishment of the Mucositis Study Group. The preparation included a comprehensive, systematic review of the literature related to mucositis and the development of evidence-based clinical practice guidelines. The reviews included literature on mucositis interventions, pathogenesis, and the risk of oral and gastrointestinal mucosal injury associated with targeted cancer therapies.
Current Guideline Publications - FREE open access to the following articles:
MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy
The MASCC/ISOO Mucositis Guidelines: dissemination and clinical impact - Lalla RV, Ashbury FD.
Systematic review of basic oral care for the management of oral mucositis in cancer patients - McGuire DB, Fulton JS, Park J, Brown CG, Correa ME, Eilers J, Elad S, Gibson F, Oberle-Edwards LK, Bowen J, Lalla RV
Systematic Review of Anti-inflammatory Agents for the Management of Oral Mucositis in Cancer Patients
Systematic Review of Antimicrobials, Mucosal Coating Agents, Anesthetics, and Analgesics, for the Management of Oral Mucositis in Cancer Patients - Saunders D, Epstein JB; Elad S; Allemano J; Bossi P; van de Wetering MD; Rao NG; Potting C; Cheng KK; Freidank A; Brennan MT; Dennis K; Bowen J; Lalla R
Systematic review of miscellaneous agents for the management of oral mucositis in cancer patients - Jensen SB, Jarvis V, Zadik Y, Barasch A, Ariyawardana A, Hovan A, Yarom N, Lalla RV, Bowen J, Elad S
Emerging Evidence on the Pathobiology of Mucositis - Al-Dasooqi N, Sonis ST, Bowen JM, Bateman E, Blijlevens N, Gibson RJ, Logan RM, Nair RG, Stringer AM, Yazbeck R, Elad S, Lalla RV
Risk of Oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis - Elting LS, Chang YC, Parelkar P et al
Supportive Care in Cancer, Volume 21, Issue 11, November 2013, ISSN: 0941-4355 (Print) 1433-7339 (Online)
The National Cancer Institute provides information on Oral Mucositis for both professionals and patients, with Spanish translations of both.
Please contact the Study Group Chairs above with your questions.